CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Bernard Escudier*, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katrina Peltola, John Wagstaff, Thomas C. Gaur, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer, on behalf of the CheckMate 025 investigators

**Article info**

**Abstract**

**Background:** The randomized, phase 3 CheckMate 025 study of nivolumab (n = 410) versus everolimus (n = 411) in previously treated adults (75% male; 88% white) with advanced renal cell carcinoma (aRCC) demonstrated significantly improved overall survival (OS) and objective response rate (ORR).

**Objective:** To investigate which baseline factors were associated with OS and ORR benefit with nivolumab versus everolimus.

**Design, setting, and participants:** Subgroup OS analyses were performed using Kaplan-Meier methodology. Hazard ratios were estimated using the Cox proportional hazards model.

**Intervention:** Nivolumab 3 mg/kg every 2 wk or everolimus 10 mg once daily.

**Results and limitations:** The minimum follow-up was 14 mo. Baseline subgroup distributions were balanced between nivolumab and everolimus arms. Nivolumab demonstrated an OS improvement versus everolimus across subgroups, including Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium risk groups; age <65 and ≥65 yr; one and two or more sites of metastases; bone, liver, and lung metastases; number of prior therapies; duration of...
prior therapy; and prior sunitinib, pazopanib, or interleukin-2 therapy. The benefit with nivolumab versus everolimus was noteworthy for patients with poor MSKCC risk (hazard ratio 0.48, 95% confidence interval 0.32–0.70). The mortality rate at 12 mo for all subgroups was lower with nivolumab compared with everolimus. ORR also favored nivolumab. The incidence of grade 3 or 4 treatment-related adverse events across subgroups was lower with nivolumab. Limitations include the post hoc analysis and differing sample sizes between groups.

**Conclusion:** The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivolumab as the standard of care in previously treated patients with aRCC.

**Patient summary:** We investigated the impact of demographic and pretreatment features on survival benefit and tumor response with nivolumab versus everolimus in advanced renal cell carcinoma (aRCC). Survival benefit and response were observed for multiple subgroups, supporting the use of nivolumab as a new standard of care across a broad range of patients with previously treated aRCC.

The trial is registered on ClinicalTrials.gov as NCT01668784.

© 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

---

1. **Introduction**

As the treatment paradigm for advanced renal cell carcinoma (aRCC) shifts in response to the development and approval of new therapies, a deeper understanding of patient baseline factors and/or disease characteristics affecting clinical outcomes is necessary and may help in guiding treatment decisions. Prognostic models for RCC have been developed that incorporate factors such as performance status, time from diagnosis to treatment, hemoglobin, calcium and lactate dehydrogenase concentrations, and neutrophil and platelet counts [1,2]. These models are limited because they were developed before the advent of modern immunotherapies and they do not include other factors that have also been shown to be associated with prognosis, such as the number and duration of prior therapies, sites of metastases, and age [3–6]. Further investigation of prognostic factors is needed for the development of risk models that more accurately reflect the current treatment landscape.

The phase 3 CheckMate 025 study in previously treated patients with aRCC demonstrated superior overall survival (OS) with nivolumab compared with everolimus [7]. Median OS was 25.0 mo (95% confidence interval [CI] 21.8–not reached [NR]) for nivolumab versus 19.6 mo (95% CI 17.6–23.1) for everolimus. The investigator-assessed objective response rate (ORR) was 25% versus 5% (p < 0.001) [7], while the confirmed ORR was 22% versus 4% [8]. Treatment with nivolumab also provided an OS benefit versus everolimus across prespecified subgroups of patients, including those with different Memorial Sloan Kettering Cancer Center (MSKCC) risk, number of prior antiangiogenic therapies, geographical region, age, and sex. [7].

The objectives of this analysis were to investigate further whether the OS and ORR benefits observed with nivolumab versus everolimus in the overall population were also observed in patients with poor prognostic baseline disease, and if demographic and pretreatment characteristics, including prior therapy, with an impact on outcomes with nivolumab can be identified.

---

2. **Patients and methods**

2.1. **Patients**

Adults with histological confirmation of aRCC with a clear-cell component were eligible. Additional eligibility criteria were reported previously [7]. Subgroups of patients were analyzed according to the following characteristics at baseline: MSKCC risk score (favorable, intermediate, poor) [2], International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score (favorable, intermediate, poor), age (<65 and ≥65 yr), number (1 and ≥1) and sites (bone, liver, lung) of metastases, prior therapy (sunitinib, pazopanib, interleukin-2), duration of first-line therapy (<6 and ≥6 mo), and number of prior therapies (1 or ≥2). Analyses are based on data collected via a case report form (data collected from an interactive voice response system was used in the previous publication) [7].

2.2. **Study design and treatments**

This was a phase 3, randomized, open-label study of nivolumab versus everolimus. The detailed study design was described previously [7]. Patients were randomized 1:1 to receive nivolumab 3 mg/kg intravenously for 60 min every 2 wk or an everolimus 10-mg tablet orally once daily.

2.3. **Endpoints and assessments**

The primary endpoint was OS, defined as time from randomization to death; the key secondary endpoint was investigator-assessed ORR, defined as the number of patients with complete response or partial response divided by the number of randomized patients. Disease assessments (per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) [9] were performed using computed tomography or magnetic resonance imaging at baseline and every 8 wk following randomization for the first year, then every 12 wk until progression or treatment discontinuation. Safety was assessed at each clinic visit. Subgroups reported here were assessed for OS, ORR, and safety.

2.4. **Study oversight**

This study was approved by the institutional review board or independent ethics committee at each center and conducted in accordance with Good Clinical Practice guidelines defined by the International Conference on...
Harmonisation. All patients provided written informed consent to participate according to the principles of the Declaration of Helsinki.

2.5. Statistical analyses

Descriptive statistics for categorical variables are reported as frequencies and percentages. OS was estimated using the Kaplan-Meier product-limit methods [10]; median OS and 95% CI were reported using Brookmeyer and Crowley methods [11]; 95% CIs were constructed via log-log transformation. Hazard ratios for nivolumab versus everolimus were estimated using the Cox proportional hazards model with treatment group as a single covariate [12]. Unstratified hazard ratios and corresponding 95% CIs were used to generate a forest plot of OS comprising each subgroup. A forest plot of the unweighted differences in ORR between nivolumab and everolimus and corresponding 95% CI using the Newcombe approach was produced across subgroups [13]. To assess whether the relationship between OS and treatment differed by various patient characteristics of interest, we separately tested the interaction between treatment and each baseline characteristic using a Cox proportional hazards model. Similarly, for ORR and treatment-related adverse event (TRAe) rates, the interaction between treatment and each baseline characteristic was tested using a logistic regression model. Continuous variables were only used for the interaction test for age (in years) and duration of prior therapy (in months); for all other subgroups, categorical variables were used. The analyses were conducted using SAS version 9 software (SAS Institute Inc., Cary, NC, USA).

3. Results

3.1. Patients

The analyses included 410 and 411 patients randomized to nivolumab and everolimus, respectively, between October 2012 and March 2014 (Supplementary Fig. 1). The distribution of patients in each subgroup was balanced between nivolumab and everolimus (Table 1). The minimum follow-up was 14 mo. The median follow-up among the 227 nivolumab-randomized and 196 everolimus-randomized patients who had not died at data cutoff was 22 mo (interquartile range [IQR] 20–25) and 22 mo (IQR 20–25). At data cutoff (June 2015), 67 of 406 nivolumab-randomized and 196 everolimus-randomized patients who had not died at data cutoff was 22 mo (IQR 19.1–26.7) with nivolumab and 17.6 mo (95% CI 15.6–19.8) with everolimus. Median OS in patients aged <65 yr was 26.7 mo (95% CI 21.8–NR) with nivolumab and 19.9 mo (95% CI 17.4–NR) with everolimus. Median OS in patients aged ≥65 yr was 23.6 mo (95% CI 18.2–NR) with nivolumab and 18.5 mo (95% CI 16.4–21.6) with everolimus.

3.2. OS by prognostic risk group

In an assessment of OS by favorable, intermediate, and poor MSKCC risk groups, median OS was longer in both arms in patients with better MSKCC scores (Fig. 1A, Fig. 2A–C). Among patients with poor risk who received nivolumab, median OS was almost double compared with everolimus (hazard ratio 0.48; Fig. 1A, Fig. 2C). Results for OS by IMDC risk group were consistent with those for MSKCC risk group (Supplementary Fig. 2A–C; Fig. 1A). The mortality rate at 12 mo for all subgroups was lower with nivolumab compared with everolimus and was particularly striking in the poor MSKCC risk group (Fig. 1A).

3.3. OS by age group

Median OS in patients aged <65 yr was 26.7 mo (95% CI 21.8–NR) with nivolumab and 19.9 mo (95% CI 17.4–NR) with everolimus. Median OS in patients aged ≥65 yr was 23.6 mo (95% CI 18.2–NR) with nivolumab and 18.5 mo (95% CI 16.4–21.6) with everolimus.

3.4. OS by number and site of metastases

Median OS in patients with one site of metastasis was NR with nivolumab and 29.0 mo (95% CI NR) with everolimus (Supplementary Fig. 3A, Fig. 1A). In patients with at least two sites of metastases, median OS was 22.2 mo (95% CI 19.1–26.7) with nivolumab and 17.6 mo (95% CI 15.6–19.8) with everolimus (Supplementary Fig. 3B, Fig. 1A).

Median OS in patients with bone metastases was 18.5 mo (95% CI 10.2–NR) with nivolumab and 13.8 mo (95% CI 7.0–16.4) with everolimus (Supplementary Fig. 4A, Fig. 1A). Median OS in patients with liver metastases was...
**Fig. 1** – Forest plots of (A) overall survival and (B) objective response rate by baseline characteristics (risk group, age group, number and sites of metastases, prior therapy). CI = confidence interval; IL-2 = interleukin-2; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC = Memorial Sloan Kettering Cancer Center; ORR = overall response rate; OS = overall survival.
Fig. 2 – Kaplan-Meier curves for overall survival by (A) favorable, (B) intermediate, and (C) poor MSKCC risk group. CI = confidence interval; HR = hazard ratio; MSKCC = Memorial Sloan Kettering Cancer Center; NR = not reached; OS = overall survival.
Fig. 3 – Kaplan-Meier curves for overall survival by (A) prior sunitinib therapy, (B) prior pazopanib therapy, and (C) prior interleukin-2 therapy. CI = confidence interval; HR = hazard ratio; NR = not reached; OS = overall survival.
18.3 mo (95% CI 13.4–26.7) with nivolumab and 16.0 mo (95% CI 8.4–21.6) with everolimus (Supplementary Fig. 4B; Fig. 1A). Median OS in patients with lung metastases was 25.0 mo (95% CI 20.4–NR) with nivolumab and 18.7 mo (95% CI 16.2–21.2) with everolimus (Supplementary Fig. S4C, Fig. 1A).

3.5. **OS by prior therapy**

Median OS in patients with prior sunitinib or pazopanib or interleukin-2 therapy was longer with nivolumab than with everolimus or was not yet reached for nivolumab (Fig. 3, Fig. 1A; reported previously for sunitinib and pazopanib in the nivolumab arm [14]).

When the overall treated population was divided according to first-line therapy duration, median OS was longer for both treatment arms in patients with ≥6 mo compared with <6 mo on first-line therapy and was longer with nivolumab compared with everolimus (Fig. 4, Fig. 1A).

Median OS in patients with one prior antiangiogenic therapy was 23.6 mo (95% CI 20.8–NR) with nivolumab and 19.9 mo (95% CI 17.7–24.7) with everolimus (Fig. 1A).

### 3.6. Interaction test for each subgroup

An interaction test of treatment and each subgroup with OS revealed a significant interaction for MSKCC risk group
There was no evidence of an interaction for other subgroups.

3.7. ORR for each subgroup

ORR favored nivolumab over everolimus in all subgroups, most notably in patients with poor MSKCC risk, aged at least 65 yr, one site of metastasis, lung metastases, prior pazopanib therapy, and two prior antiangiogenic therapies (Fig. 1B). There was no evidence of an interaction between treatment and each subgroup with ORR.

3.8. Safety for each subgroup

The incidence of grade 3 or 4 TRAEs was lower in the nivolumab arm compared with the everolimus arm across subgroups (Table 2). The incidence of grade 3 or 4 TRAEs in the nivolumab arm was half or less than half the incidence observed with everolimus in the following subgroups: favorable MSKCC risk (15% vs 40%); favorable IMDC risk (20% vs 41%); intermediate IMDC risk (17% vs 36%); at least 65 yr of age (16% vs 39%); one site of metastasis (15% vs 33%); lung metastases (17% vs 37%); prior interleukin-2 therapy (19% vs 38%); at least 6 mo on first-line therapy (17% vs 37%); and two prior antiangiogenic therapies (17% vs 36%; Table 2). There was no evidence of an interaction between treatment and each subgroup with any TRAE.

4. Discussion

With a minimum follow-up of 14 mo in previously treated patients with aRCC, OS and ORR favored nivolumab over everolimus for multiple subgroups. Within the nivolumab arm, ORR for most subgroups was similar and consistent with the overall ORR reported previously [7].

Median OS was greater and mortality rate was lower with nivolumab than with everolimus in all MSKCC risk groups, with the largest difference in patients with poor risk. The small number of events and short duration of follow-up in the favorable risk group limited the ability to observe robust OS differences between arms. The large difference for poor-risk patients suggests that further investigation of the characteristics of these patients, such as tumor biology, is needed to better understand this finding. One explanation, yet to be formally analyzed, is the potential presence of a higher mutational load in poor-risk patients, a phenomenon that in some cases has been correlated with better efficacy of PD-1 inhibitors. This is

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Nivolumab Any grade</th>
<th>Nivolumab Grade 3–4</th>
<th>Everolimus Any grade</th>
<th>Everolimus Grade 3–4</th>
</tr>
</thead>
<tbody>
<tr>
<td>All treated patients</td>
<td>319 (79)</td>
<td>76 (19)</td>
<td>349 (88)</td>
<td>145 (37)</td>
</tr>
<tr>
<td>MSKCC risk score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Favorable</td>
<td>116 (85)</td>
<td>21 (15)</td>
<td>131 (93)</td>
<td>56 (40)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>143 (74)</td>
<td>36 (19)</td>
<td>160 (87)</td>
<td>63 (34)</td>
</tr>
<tr>
<td>Poor</td>
<td>60 (78)</td>
<td>19 (25)</td>
<td>58 (80)</td>
<td>26 (36)</td>
</tr>
<tr>
<td>IMDC risk score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Favorable</td>
<td>46 (84)</td>
<td>11 (20)</td>
<td>67 (99)</td>
<td>28 (41)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>189 (78)</td>
<td>41 (17)</td>
<td>202 (87)</td>
<td>83 (36)</td>
</tr>
<tr>
<td>Poor</td>
<td>71 (76)</td>
<td>21 (22)</td>
<td>64 (80)</td>
<td>26 (33)</td>
</tr>
<tr>
<td>Not reported</td>
<td>13 (81)</td>
<td>3 (19)</td>
<td>16 (100)</td>
<td>8 (50)</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 65 yr</td>
<td>200 (79)</td>
<td>51 (20)</td>
<td>199 (86)</td>
<td>81 (35)</td>
</tr>
<tr>
<td>≥65 yr</td>
<td>119 (78)</td>
<td>25 (16)</td>
<td>150 (90)</td>
<td>64 (39)</td>
</tr>
<tr>
<td>Number of sites of metastases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>57 (85)</td>
<td>10 (15)</td>
<td>62 (90)</td>
<td>23 (33)</td>
</tr>
<tr>
<td>≥2</td>
<td>262 (77)</td>
<td>66 (19)</td>
<td>287 (88)</td>
<td>122 (37)</td>
</tr>
<tr>
<td>Site of metastases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone</td>
<td>51 (67)</td>
<td>13 (17)</td>
<td>50 (75)</td>
<td>13 (19)</td>
</tr>
<tr>
<td>Liver</td>
<td>78 (80)</td>
<td>22 (22)</td>
<td>72 (85)</td>
<td>31 (36)</td>
</tr>
<tr>
<td>Lung</td>
<td>215 (78)</td>
<td>46 (17)</td>
<td>232 (88)</td>
<td>97 (37)</td>
</tr>
<tr>
<td>Prior therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunitinib</td>
<td>197 (78)</td>
<td>46 (18)</td>
<td>220 (88)</td>
<td>89 (35)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>103 (82)</td>
<td>24 (19)</td>
<td>114 (89)</td>
<td>45 (35)</td>
</tr>
<tr>
<td>Interleukin-2</td>
<td>37 (88)</td>
<td>8 (19)</td>
<td>30 (88)</td>
<td>13 (38)</td>
</tr>
<tr>
<td>Time on first-line therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 6 mo</td>
<td>85 (79)</td>
<td>24 (22)</td>
<td>109 (88)</td>
<td>44 (35)</td>
</tr>
<tr>
<td>≥6 mo</td>
<td>234 (78)</td>
<td>52 (17)</td>
<td>240 (88)</td>
<td>101 (37)</td>
</tr>
<tr>
<td>Prior antiangiogenic therapies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>240 (76)</td>
<td>61 (19)</td>
<td>264 (87)</td>
<td>111 (37)</td>
</tr>
<tr>
<td>2</td>
<td>76 (85)</td>
<td>15 (17)</td>
<td>85 (90)</td>
<td>34 (36)</td>
</tr>
</tbody>
</table>

IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC = Memorial Sloan Kettering Cancer Center.

a Two grade 5 events (septic shock and acute bowel ischemia).

b One grade 5 event.
possibly because of the higher levels of lymphocytes expressing immune inhibitory signals in the tumor microenvironment that can be targeted by PD-1 inhibitors [15,16]. The improved OS with nivolumab versus everolimus in patients with liver or bone metastases, which are associated with high incidence and poor prognosis [3,17,18], further demonstrates that patients with poor prognostic features benefit from treatment with nivolumab.

There are some suggestions that response to nivolumab may be influenced by prior effect of tyrosine kinase inhibitors on the tumor microenvironment or their potential immune effect [14,19,20]. Although this study did not directly address the tumor microenvironment or the sequence of therapy, we did observe that OS was improved with nivolumab for all three prior therapies evaluated (sunitinib, pazopanib, and interleukin-2). Interleukin-2 is currently indicated in first-line treatment for a select group of patients with excellent performance status and normal organ function [21]. The small number of patients with prior interleukin-2 treatment enrolled and clinical selection criteria that impact decisions to treat with interleukin-2 preclude substantial clinical inferences. However, the favorable hazard ratio for nivolumab versus everolimus may imply a special impact of immune system manipulation by immunotherapies such as interleukin-2 that may result in benefit from subsequent treatment with an immune checkpoint inhibitor.

the superior OS for nivolumab was maintained regardless of the duration of first-line therapy, suggesting that a switch from a tyrosine kinase inhibitor to nivolumab, either for a lack of response or toxicity (subgroup with <6 mo of first-line therapy) or following potentially successful first-line therapy (subgroup with ≥6 mo of first-line therapy) provides a survival benefit.

The incidence of all-grade and grade 3 or 4 TRAEs in each subgroup was lower with nivolumab than with everolimus and was similar to TRAEs noted in the overall population [7]. Notably, both younger and older patients had a similar incidence of grade 3 or 4 TRAEs. This observation, coupled with the improved OS with nivolumab versus everolimus in younger and older patients, suggests that older age did not preclude clinical benefit.

Some limitations should be noted, including the post hoc nature of the analyses and the differing sample sizes within subgroups. The small sample size in some subgroups limits the interpretation of those results and may have contributed to the large range for some 95% CIs associated with hazard ratios for death and difference in ORR. Analyses with more patients are needed to validate those results. Furthermore, in the subgroup analyses of individual sites of metastases, some patients with multiple sites of metastases were represented in more than one subgroup, which complicates interpretation of OS by number of sites of metastases.

The broad benefit of nivolumab versus everolimus in terms of OS and ORR with respect to patient demographics, clinical characteristics, and prior therapies may provide additional insight that will allow clinicians to make informed decisions. With the increasing number of therapies available to treat aRCC, predicting outcomes, possibly through the development of nomograms based on baseline disease characteristics and prior therapies, will help to increase the individualized approach to treatment in an effort to improve survival [22]. Further research should focus on the development of predictive models of outcomes more aligned with immunotherapy in accordance with findings from this study.

In conclusion, consistent with the benefit demonstrated in the overall population from CheckMate 025 [7], a trend for OS and ORR benefit with nivolumab versus everolimus was observed for multiple subgroups, including prognostic risk categories, age, number and sites of metastases, and prior therapies, without specific safety concerns. Efficacy with nivolumab is notable in patients with poor risk features, including those in the poor MSKCC risk group, those with bone metastases, and those with more than one site of metastasis. These results further support the use of nivolumab as a new standard of care [21,23,24] for a broad range of patients with previously treated aRCC.


Author contributions: Bernard Escudier had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Motzer, Waxman.

Acquisition of data: Waxman, Zhao.

Analysis and interpretation of data: All authors.

Drafting of the manuscript: Escudier, Motzer.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Zhao.

Obtaining funding: None.

Administrative, technical, or material support: None.

Supervision: None.

Other: None.

Financial disclosures: Bernard Escudier certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Frede Donskov has received institutional research funding from Novartis, GlaxoSmithKline, and Pfizer. Bernard Escudier has received honoraria from Bayer, Novartis, Pfizer, Bristol-Myers Squibb, and Exelixis. Thomas Gauer owns stock in Bayer AG; has received consulting or advisory fees from MSD, Merck Serono, Novartis, and Bristol-Myers Squibb; and has received travel and accommodation expenses from Boehringher Ingelheim, Merck Serono, Novartis, MSD, Bayer Healthcare, Hoffmann-La Roche, and Bristol-Myers Squibb. Saby George has an immediate family member employed by Amgen, and has received research funding from Bristol-Myers Squibb, Novartis, Pfizer, Bayer, Acceleron, and Agensys. Howard Gurney has received consulting or advisory fees from Astellas, Bristol-Myers Squibb, Novartis, and Pfizer. Hans Hammers has received consulting or advisory fees from Bristol-Myers Squibb, Exelixis, Pfizer, and Cerulean, and research funding from SFJ, Bristol-Myers Squibb, Exelixis, Newlink, Pfizer, GlaxoSmithKline, and Tracon. David McDermott has received consulting or advisory fees from Bristol-Myers Squibb, Merck, Genentech, Novartis, Pfizer, Eisai, and Exelixis, and institutional research funding from Promethius Labs. Robert Motzer has received...
consulting or advisory fees from Novartis, Eisai, and Pfizer, and research funding from Exelixis, Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Eisai, and Pfizer. Katrina Peltola has received advisory fees from MSD, Bristol-Myers Squibb, Lilly, Sanofi, Astellas, Pfizer, and Novartis, and travel compensation from Pierre Fabre and Bristol-Myers Squibb. Elizabeth Plimack has received consulting or advisory fees from Merck, Dendreon, Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Acceleron Pharma, and Genentech/Roche, and institutional research funding from Merck, Bristol-Myers Squibb, GlaxoSmithKline, Acceleron Pharma, Dendreon, Lilly, and AstraZeneca, and has an institutional interest in US Patent No. 14/588,503. Giuseppe Procopio has received grants from Bayer and personal fees from Astellas, Bristol-Myers Squibb, Janssen, Novartis, and Pfizer. Padmane Shama has received leadership fees from Kite Pharma, Jounce, and EVELO; consultant or advisor fees from Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, and Amgen; investigator fees from Bristol-Myers Squibb, GlaxoSmithKline, and AstraZeneca. She has investment interests in Jounce, Kite Pharma, EVELO, and owns a patent licensed to Jounce. Her spouse has received leadership fees from Kite Pharma, Jounce, and Neon; has investment interests in Jounce, Kite, and Neon; and has an interest in patents licensed to Bristol-Myers Squibb, Jounce, and Merck. Jeffrey Sosman has received honoraria and consulting or advisory fees from Novartis, Genentech, Array, and Merck; and research funding from Bristol-Myers Squibb, Biomedical Valley Development, and GlaxoSmithKline. Scott Tykodi has received consulting or advisory fees from Prometheus Laboratories and Amgen, and institutional research funding from Genentech, Bristol-Myers Squibb, Exelixis, Argus Therapeutics, GlaxoSmithKline, and Prometheus. An immediate family member of John Wagstaff has received honoraria from Roche, Bristol-Myers Squibb, Pfizer, Novartis, and MSD; consulting or advisory fees from Roche, Bristol-Myers Squibb, Pfizer, Novartis, and MSD; and travel and accommodation expenses from Bristol-Myers Squibb and MSD. Ian Waxman and Huanyu Zhao are employed by and hold stock in Bristol-Myers Squibb. Daniel Castellano, Sandhya Srinivas, and Takeshi Ueda have nothing to disclose.

Funding/Support and role of the sponsor: This study was sponsored by Bristol-Myers Squibb and Ono Pharmaceutical Company Limited. The sponsors contributed to the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript in collaboration with the investigators and authors of this report.

Acknowledgments: We thank the patients and their families, as well as the investigators and participating study teams, for making this study possible. Medical writing assistance was provided by Jennifer Granit of PAREXL company and was funded by Bristol-Myers Squibb.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.eurouro.2017.02.010.

References


